Yufei Liu, MD, PhD, discussed the importance of careful data interpretation to accurately assess the efficacy of new ...

A decade into reformulating Pfizer’s oral renal cell carcinoma drug Inlyta (axitinib) into a treatment that can be injected ...

KEYTRUDA’s safety profile in this trial was found to be in line with previous studies, without any new safety concerns ...

Breast cancer is the second most common cancer and a leading cause of cancer-related death. More than 2 million cases of breast cancer were diagnosed in 2022 with more than 665,000 deaths globally.

Researchers have found a potential new way to improve the treatment of multiple sclerosis (MS) using a novel combined therapy. The results build on two harmonized Phase I clinical trials, focusing on ...

Bispecific antibodies (bsAbs) are engineered to target 2 different epitopes simultaneously. About 75% of the 16 clinically ...

Avera participates in numerous clinical trials, including ones that are Phase 1. In this Avera Medical Minute, we share what ...

Moderna, Inc. (NASDAQ:MRNA) today announced that the first participant in the U.S. has been dosed in the Nova 301 Trial, a pivotal Phase 3 randomized clinical trial evaluating the efficacy, safety, ...

The biotech expects that stopping enrollment for KarMMa-9, a trial evaluating early use of the multiple myeloma cell therapy Abecma, should save it $80 million in the near term.